As the latest generation in the XIENCE™ family of stents, the stent platform that consistently delivers successful patient outcomes – not only in the cath lab, but also long-term.4 This stent also offers:
During percutaneous coronary interventions (PCI), small differences between stents can be the determining factor for the patient’s acute and long-term outcomes.4 XIENCE Skypoint™ Stent has a number of new features that offer broader treatment options to interventional cardiologists (ICs).
Updated features include:
These new features can help clinicians treat the increasingly wide range of lesions encountered in real-world patients.
Compared to other DES, several key factors account for XIENCE™ Stent’s unparalleled clinical outcomes.1
The XIENCE™ Stent is designed to conform to vessel anatomy,9 as well as to reduce inflammation and minimize thrombogenicity.10 Get more details about the stent design.
Unlike other stents’ polymer coatings, the Abbott fluoropolymer interacts with blood proteins in a manner that reduces thrombus formation.10 View the visual evidence of fluoropolymer safety—significantly less inflammation and thrombus formation—compared to competitors’ stents.
The choice for XIENCE™ Stent is the drug everolimus. This broadly therapeutic drug is safe and stable over the long term.11 See how the everolimus elution correlates to the restenosis cascade.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?